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Abstract
Background: Disability-adjusted life years (DALYs) link data on disease occurrence to health outcomes, and they
are a useful aid in establishing country-specific agendas regarding cancer control. The variables required to
compute DALYs are however multiple and not readily available in many countries. We propose a methodology that
derives global DALYs and validate variables and DALYs based on data from various cancer registries.
Methods: We estimated DALYs for four countries (Norway, Bulgaria, India and Uganda) within each category of the
human development index (HDI). The following sources (indicators) were used: Globocan2008 (incidence and
mortality), various cancer registries (proportion cured, proportion treated and duration of disease), treatment
guidelines (duration of treatment), specific burden of disease studies (sequelae and disability weights), alongside
expert opinion. We obtained country-specific population estimates and identified resource levels using the HDI,
DALYs are computed as the sum of years of life lost and years lived with disabilities.
Results: Using mortality:incidence ratios to estimate country-specific survival, and by applying the human
development index we derived country-specific estimates of the proportion cured and the proportion treated. The
fit between the estimates and observed data from the cancer registries was relatively good. The final DALY
estimates were similar to those computed using observed values in Norway, and in WHO’s earlier global burden of
disease study. Marked cross-country differences in the patterns of DALYs by cancer sites were observed. In Norway
and Bulgaria, breast, colorectal, prostate and lung cancer were the main contributors to DALYs, representing 54%
and 45%, respectively, of the totals. These cancers contributed only 27% and 18%, respectively, of total DALYs in
India and Uganda.
Conclusions: Our approach resulted in a series of variables that can be used to estimate country-specific DALYs,
enabling global estimates of DALYs and international comparisons that support priorities in cancer control.
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Background
Cancer is one of the major causes of morbidity and mor-
tality globally, with 12.7 new cancer cases and 7.6 mil-
lion cancer deaths worldwide in 2008 [1,2]. Despite
successes in the prevention, early detection and screen-
ing of cancers in some populations, the number of new
cancer cases is increasing globally, partly due to popula-
tion ageing and growth, but also as a result of changing
prevalence and distribution of the major risk determi-
nants for cancer in different populations. As a result,
cancer is projected to become one of the main causes of
death in low, middle and high income countries in the
coming decades [1].
In describing cancer patterns and trends as a means to
plan and evaluate cancer control policies, incidence, mor-
tality and survival are considered the standard set of indi-
cators. This study provides a methodological framework
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for estimating an indicator that integrates the above mea-
sures with metrics related to non-fatal outcomes.
Disability-adjusted life years (DALYs) measure loss of
health as a result of illness in the population relative to
the ideal scenario where everyone in the population lives
into old age in full health [3]. It is a time-based measure
that combines the time lost due to premature mortality
(years of life lost, or YLLs) and the duration of disability
(years of life lived with a disability, or YLDs) in survivors.
One lost DALY equates to one lost year of “healthy” life,
either as a result of premature death from the disease, or
because of disease-related illnesses or disability [3]. Sur-
vival for a number of common cancers has been increas-
ing in the last decades, resulting in an ever-increasing
number of survivors [4], some living with cancer sequelae.
By estimating disability-adjusted life years (DALYs), two
key components of the burden of cancer are captured: one
related to premature mortality, the other to the loss of
‘healthy’ life years related to the morbidity that follows a
diagnosis of cancer [3].
The paper aims to provide an overview of methodo-
logical approaches to calculate sex-specific DALYs for
27 cancer types based on the modeling of indicators
derived from numerous epidemiological histories for
each of the common cancer sites. Cancer-specific
DALYs have been previously estimated in a global or
national context [1,5,6]. Besides taking a country-
specific approach to build up the global picture, we
propose a unified framework that takes into account
the natural history of each cancer site under study.
The key parameters - incidence, mortality, survival and
the proportion cured / treated are estimated, based on
the most recent population-based data or using results
from specific studies. The basic calculation methods
developed for the global burden of disease (GBD)
study [3] were used and adapted. Finally we validated
the general disease model on the basis of an assumed
set of natural histories for each of the common cancer
sites for four countries, one within each category of
the human development index (HDI): Norway, Bul-
garia, India and Uganda.
Methods
To calculate DALYs [3], YLLs and YLDs are independ-
ently calculated and then combined in a single summary
measure (Formula 1).
DALY ⋅ ¼ YLL⋅þ ⋅YLD ð1Þ
YLLs were calculated by multiplying the number of
cancer-specific deaths at a given age by the standard life
expectancy for that age (or age group, Formula 2). As
has been done in earlier global burden of disease project,
we used the model life-table West with a life expectancy
at birth of 82.5 years for women and 80 years for men
[7]. We used the life expectancy at the mid-point for
each age group (0–14, 15–39, 40–44, 45–49,. . . , 70–74,
75 and over), corresponding to the age-specific mortality
data available on a global basis (see below).
YLL ¼
X
X
dxe
∗
x ð2Þ
where d= death, x= age, e* standard expectation of life
at age x.
YLDs were derived as the product of the number of
new cases, the average duration of the disability and dis-
ability weightings for the condition (or disease state, For-
mula 3). Disability weights represent a value preference
that scales a condition or state from 0 (full health) to 1
(death) [3]. To allow comparison between countries,
YLLs and YLDs were age standardized by the direct
method, using the world standard population [8].
YLD ¼
X
x;y
ix;ydwydx;y ð3Þ
where i= incidence, x= age, y= disease phase, dw=Dis-
ability weight, d= duration of disability.
The general form of the proposed natural history model
for cancer is illustrated in Figure 1. We assumed three
possible pathways for newly-diagnosed cancer cases:
I. Those who were treated (p) and then cured (s) from
cancer, underwent a period of disability during the
primary diagnosis and therapy phase
(duration = LD), and a period of disability during
remission (LR1), during which patients underwent
intensive follow-up to detect recurrence or
dissemination. A proportion of treated patients who
were considered cured continued to live
permanently with one (or more) cancer sequelae.
II. Those who died from cancer after treatment (p-s),
underwent a period of disability in the following
phases: (i) primary diagnosis and therapy (LD), (ii)
the remission period LR2 (for which the duration
was estimated as the time between treatment and
death minus 4 months) [5], (iii) the pre-terminal
phase LM and (iv) the terminal phase LT. LM
constitutes the phase where cancer has
disseminated and was set to last for 3 months [5].
The terminal phase LT, where patients are at the
final stages of living, was uniformly set for
1 month [5].
III. Those who did not receive treatment (1-p)
underwent a period of disability during the
pre-terminal (LM) and terminal phases (LT). This
group was considered to comprise advanced
cancer cases, who would have received palliative
treatment only.
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Figure 1 a: Three-stage natural disease history for cancer. b: Two-stage disease history model.
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On the basis of this natural history model and the
parameters contained within, we estimated DALYs for
27 cancers. In this paper we present and validate DALYs
for four countries, one within each category of the HDI:
Norway, Bulgaria, India and Uganda, in 2008. The main
sources of data and the estimation methods are set out
below.
Cancer incidence and mortality
The incident number of cancer cases and deaths accord-
ing to sex and age were extracted from GLOBOCAN
2008 [2] for 27 cancer sites: lip and oral cavity (ICD-
10 C00-08), nasopharyx (C11), other pharynx (C09-10,
C12-14), oesophagus (C15), stomach (C16), colorectum
(C18-21), liver (C22), gallbladder (C23-24), pancreas
(C25), larynx (C32), trachea, bronchus and lung (C33-34),
melanoma of skin (C43), Kaposi sarcoma (C46), breast
(C50), cervix uteri (C53), corpus uteri (C54), ovary (C56),
prostate (C61), testis (C62), kidney (C64-66), bladder
(C67), brain, nervous system (C70-72), Hodgkin lymph-
oma (C81), non-Hodgkin lymphoma (C82-85, C96,
B21.1-2), multiple myeloma (C88, C90) and leukemia
(C91-95)). Age was stratified into 10 groups (0-14, 15-39,
40-44, 45-49, . . ., 70-74, 75 and over).
Proportion cured, proportion treated and proportion with
sequelae
Proportion cured (s)
The proportion of patients statistically cured from can-
cer is reached when a group of patients have (almost)
the same mortality as the general population [9]. To de-
termine the country and cancer-specific cured propor-
tions, we firstly estimated case fatality as the ratio of
mortality (the number of deaths, M) to incidence (num-
ber of new cases, I), which is also a proxy for 5-year sur-
vival as 1 – (M/I) [10,11], based on the GLOBOCAN
estimates. Secondly, we obtained a smoothed function of
the estimated survival regressed according to the levels
of the human development index (HDI) [12] via a log-
linear regression model. Here HDI was chosen because
it is a composite of various factors including investment
in health infrastructure, and is expected to predict sur-
vival. Fourthly, we calculated the ratios of the proportion
cured to 5-year survival from a published report from
the Cancer Registry of Norway [13]. Finally the ratios
(proportion cured:survival) were applied to the country-
specific fitted values of survival to provide corresponding
country-specific estimates of the proportion cured.
Proportion treated (p)
This measure was estimated as the percentage of
patients who received either surgery, chemotherapy,
radiotherapy or a combination of two or more of the
aforementioned treatments. We applied the ratio of the
proportion treated (from the Cancer Registry of Norway
(for solid tumors) and of Ireland (for Kaposi sarcoma
and haematological malignancies)) to the reported pro-
portion cured, [13] to the estimated proportion cured
derived as described above, to obtain country-specific
proportions treated.
Proportion of survivors living with sequelae
Sequelae among survivors are commonly related to the
cancer-specific treatment. Estimating the distribution of
survivors who are living with sequelae requires system-
atic assessment of the available evidence on treatment
types, the survival among specific treatment group, as
well as the duration and severity of the disability. These
data are generally not available; and where they were,
were mainly from high-resource countries with highly-
developed cancer registration systems. We therefore
could only obtain for a number of limited cancer sites, a
set of disabling sequelae (Table 1). The final estimates
for the proportion of survivors living with sequelae were
derived by combining several information sources, in-
cluding cancer registries, peer-reviewed literature [14-20]
and oncological treatment guidelines [21]. For example:
for ovarian, cervical and corpus uteri cancers, the stand-
ard treatment is hysterectomy; thus all cured patients
were assumed to have had this treatment, with infertility
as a sequelae.
Duration of different phases of disease
Time to death (TD)
The median survival time of those who will die as a con-
sequence of one of 13 cancers (oropharyngeal,
oesophageal, stomach, colorectal, liver, gallbladder, pan-
creatic, lung, ovarian, kidney, bladder, central nervous
system cancers and leukemia), as reported by Småstuen
et al [13], was used. As this could not be estimated for
other sites, we assumed the following times (in paren-
theses) for the specific cancer sites: non-Hodgkin lymph-
oma (5 years), cancers of the larynx, Kaposi sarcoma,
cervix uteri, corpus uteri, testis, thyroid, Hodgkin
lymphoma and multiple myeloma (1 year). Time to
death (Table 2) was assumed to be a biological constant
that was the same in all countries.
Time to cure (TC)
Estimates of the time to cure were obtained by means of
visual inspection of cancer-specific relative cumulative
and conditional survival curves obtained from cancer
survival report of the Cancer Registry of Norway in 2007
[13]. We assumed that cure is attained when the condi-
tional relative survival curve reaches above 90% and sta-
bilizes (towards its asymptote). The time to cure was
assumed to be a biological constant, and thus fixed
across all countries (Table 2).
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Table 1 Proportion with sequelaes and disability weights for selected cancer sites and data sources
Sites/sequelae Source of data Proportion* Disability
weights
Remarks
Rectum
Stoma Morris E et al [22] 13% among
colorectal
cancer survivors
0.211 Not all rectal cancer patients
had treatment leading to stoma.
Victorian weights for stoma.
Larynx
Loss of speech Eindhoven cancer registry 6% 0.20 Proportion receiving total
laryngectomy.
Melanoma of Skin
- Disfigurement grade I De Vries et al [14] 25% 0.016 Lesion was on the face & Breslow
thickness ≤2 mm or on the leg and
arm & Breslow thickness >2 mm.
GBD weight for cleft lip treated.
- Disfigurement grade II Male: 7%,
Female: 3%
0.056 Lesion was on the face & Breslow
thickness >2 mm. GBD weight
for other skin disease
Breast
Mastectomy European average [23] 45% 0.20 Provisional weights
Cervix uteri
- Primary infertility Hysterectomy is the standard
treatment for this cancer
<40 years: 100% 0.18 Standard treatment including
hysterectomy.
- Secondary infertility 40-50 years: 100% 0.10 Provisional weights
Corpus uteri cancer
- Primary infertility Hysterectomy is the standard
treatment for this cancer
<40 years: 100% 0.18 Standard treatment
including hysterectomy.
- Secondary infertility 40-50 years: 100% 0.10 Provisional weight
Ovary
- Primary infertility Hysterectomy is the standard
treatment for this cancer
<40 years: 100% 0.18 Standard treatment
including hysterectomy.
- Secondary infertility 40-50 years: 100% 0.10 Provisional weight
Prostate
- Incontinence Kvale R et al [15], 5% 0.157
- Impotence Johansson et al [16] 10% 0.195
- Primary infertility <40 years: 25% 0.18 Infertility due to prostatectomy.
Impotence has a higher weight
so we assumed only 15% had
disability due to infertility
- Secondary infertility 40-60 years: 25% 0.10 Provisional weight
Testis 16%
- Primary infertility Brydoy M et al [17] <40 years: 34% 0.18
- Secondary infertility 40-60 years: 27% 0.10 Provisional weight
Bladder (therapy removes prostate)
- Incontinence Fossa S et al [18] 5% 0.157
- Impotence Hardt [19] 10% 0.195
- Primary infertility <40 years: 16% 0.18 Infertility due to prostatectomy.
Impotence has a higher weight
so assumed only 15% had
disability due to infertility
- Secondary infertility 40-60 years: 16% 0.10 Provisional weight
Data source for weights: Dutch and Victorian burden of disease study and the Global Burden of Disease project [3,5,6].
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Duration of diagnosis and treatment (LD)
A general delay of 2 months, prior to treatment onset,
was assumed. This includes a period of one month for
cancer diagnosis, an initial period that includes diagnos-
tic work-up and ascertainment of stage and degree of
dissemination of the disease. In many countries, delivery
of cancer treatment may be delayed up to a few weeks
or months after diagnosis [30] e.g. median time between
diagnosis and treatment for surgical and radiotherapy of
rectal cancer patients in the Netherlands is reported as
between 18 and 30 days [31]; we assumed a general
delay of 1 month.
Evidence-based guidelines for cancer treatment by site
in the Netherlands were examined to determine the dur-
ation of each treatment modality [21]. An exception to
this rule was treatment of melanoma of skin, for which
we assumed a period of one month for diagnosis and
treatment (including possible delays to the latter). The
time period for diagnosis and treatment (LD) was
assumed to be constant across all countries (Table 2).
Disability weights
Disability weights reflect the social preference or value
attached to different states of health. In calculating
DALYs, the average population weight (or preference)
was used, instead of individual values. The weights
were estimated using the person trade-off method
whereby participants were asked to value the severity
of various conditions on a scale of 0 (full health) to 1
(a health state equivalent to death) relative to a set of
pre-determined weights of several conditions [3]. Dis-
ability weights for each phase of the natural history of
cancer by cancer site were derived from Dutch and
Victorian burden of disease studies, as well as earlier
estimates from the global burden of disease project
[3,5,6] (Tables 1 and 3).
Discounting and age weighting
Controversies exist as to whether discounting should be
applied when DALYs are measured [32]. Earlier studies
of the burden of disease have applied a discount to the
future years lost, so to give more weight to lost years
that occur nearer to the present time [3]. To study the
effect of time discounting on the estimated of DALYs,
we applied a 3% time discount rate [7]. To give more
relevance to deaths in young and middle age, we also
tested the use of non-uniform age weights, we used the
standard formula:
Xw ¼ Cxβx ð4Þ
where Xw is the weighted age (years), C and β are con-
stant and x is age (in years) [3].
Sensitivity analyses
We examined the impact on the estimate of DALYs of
several different assumptions in the calculation:
1. Estimates of the proportion cured and proportion
treated by country. Estimates from Norway,
based on the reported proportion cured and
proportion treated from the Cancer Registry of
Norway, were compared with those derived
through the modeling exercises, described above.
We also validated the modeled estimates of
proportion treated against observed treatment
data obtained from eight Cancer Registries
(Bulgaria, India (Mumbai), Ireland, Jordan,
Norway, Poland (Holy Cross), the Republic of
Korea and Slovakia).
Table 2 Estimates of time to cure (years), time to death
(years), and time for diagnosis and treatment (years)
according to cancer, as applied to all countries
Cancer sites Time to
cure
Time to
death
Time for diagnosis
and therapy
Lip oral cavity 7.00 3.00 0.58
Nasopharynx 7.00 3.00 0.58
Other pharynx 7.00 3.00 0.58
Oesophagus 4.00 0.70 0.50
Stomach 8.00 0.60 0.50
Colorectum 7.00 1.60 1.08
Liver 5.00 0.40 0.50
Gallbladder 5.00 0.70 0.33
Pancreas 4.00 0.40 0.50
Larynx 5.00 1.00 0.50
Lung 6.00 0.60 0.50
Melanoma of the skin 5.00 1.00 0.08
Kaposi sarcoma 0.00 1.00 0.50
Breast 7.00 5.70 0.92
Cervix uteri 4.00 1.00 0.42
Corpus uteri 6.00 1.00 0.67
Ovary 8.00 2.40 0.67
Prostate 10.00 6.70 0.58
Testis 2.00 1.00 0.42
Kidney 5.00 2.70 0.42
Bladder 4.00 2.20 0.33
Brain, nervous system 5.00 1.90 0.50
Thyroid 2.00 1.00 0.42
Hodgkin Lymphoma 6.00 1.00 0.92
Non- Hodgkin Lymphoma 5.00 5.00 0.92
Multiple myeloma 5.00 1.00 1.00
Leukaemia 4.00 1.80 1.00
Data sources: (1) Time to cure and time to death: Cancer Registry of Norway
[13,24], the survival of cancer patients diagnosed in Nordic countries in
1964-2003 [25-29] and (2) Time for diagnosis and therapy: Clinical guideline
for cancer treatment and care [21].
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2. Use of a two-stage natural history model. We sought
to assess the impact on the DALYs if a simpler two-
stage model, in which data on treatment is no longer
required, was used (Figure 1b). In this model, all
patients are assumed to go through the diagnosis
and treatment phase. As most cancer registries do
not have complete and accurate data on the nature
of cancer treatment (curative or palliative), or
cancer-specific treatment (surgery, radiotherapy etc),
the two-stage disease model has its advantages.
Patients who eventually are cured (s) went into a
remission phase before cure or continue to live with
sequelae. The second (uncured) group went first
into remission, then pre-terminal and terminal
phases and eventually died from cancer.
3. Using the reported proportion of advanced cancer
cases as a proxy for the proportion that did not
receive treatment. The lack of high-quality
treatment data worldwide is a concern in
calculating DALYs and we assessed whether the
proportion of cases with distant cancer is a better
proxy for the proportion of cases who did not
receive curatively-intended treatment in the
three-stage natural history disease.
4. Impact of discounting and age weighting
(as described above).
In the text that follows we report the results of each of
these validation exercises the estimated DALYs in four
countries (Norway, Bulgaria, India and Uganda), popula-
tions representative of the four quartiles of the human
development index (very high, high, medium and low,
respectively). The DALYs are presented in these coun-
tries, examining the relative contribution of YLL and
YLD to the DALYs according to cancer site.
Results
Estimates in four countries: Disability-adjusted live years
In the four countries considered (Norway, Bulgaria,
India and Uganda) the total DALYs lost due to the 27
cancer sites included in this study were 4503, 5569,
3022, and 6491 per 100,000 population respectively
(Figure 2). The main differences between countries
were: (1) Rankings of the various cancer types and (2)
Proportion of YLDs or YLLs over DALYs. Cancer of
the lung, colorectum, prostate, breast and cervix uteri
contributed to the largest lost in DALYs in Norway or
Bulgaria. In India besides lung, breast and cervical
cancers, cancer of the oral cavity was the main cause
of lost in healthy years. In Uganda, HIV/AIDS defining
cancers such as Kaposi sarcoma, non-Hodgkin lymph-
oma and cervical cancers were identified as making
the largest contribution to DALYs, in addition to
oesophageal and prostate cancer for men and breast
cancer for women.
In all countries most of the DALYs lost are due to early
death from cancers i.e. YLLs over DALYs were 81%, 90%,
94% and 97% in Norway, Bulgaria, India and Uganda.
The YLDs had more importance in cancers that are both
common (high incidence) and with moderate or good
survival, such as breast, colorectum, prostate and cervical
cancers. Generally, the fraction of DALYs represented by
YLDs was greater in the more developed countries. For
example for breast cancer, the proportions of YLDs over
DALYs were 38%, 26%, 15% and 11% in Norway, Bulgaria,
India and Uganda respectively. The proportions of YLDs
over DALYs were also substantial for testicular cancer
(79% in Norway) and Hodgkin lymphoma (55% in
Norway).
Table 3 Disability weights for each disease state
according to cancer site
Cancer sites Disease states
Diagnosis
& initial
treatment
Control Pre-terminal Terminal
Lip oral cavity 0.56 0.37 0.90 0.93
Nasopharynx 0.56 0.37 0.90 0.93
Other pharynx 0.56 0.37 0.90 0.93
Oesophagus 0.56 0.37 0.93 0.93
Stomach 0.53 0.38 0.93 0.93
Colorectum 0.43 0.20 0.83 0.93
Liver 0.43 0.20 0.83 0.93
Gallbladder 0.43 0.20 0.83 0.93
Pancreas 0.43 0.20 0.83 0.93
Larynx 0.56 0.37 0.90 0.93
Lung 0.72 0.47 0.91 0.93
Melanoma of skin 0.26 0.19 0.81 0.93
Kaposi Sarcoma 0.51 0.14 0.83 0.93
Breast 0.54 0.26 0.79 0.93
Cervix uteri 0.43 0.20 0.75 0.93
Corpus uteri 0.43 0.20 0.75 0.93
Ovary 0.43 0.20 0.75 0.93
Prostate 0.27 0.18 0.64 0.93
Testis 0.27 0.18 0.64 0.93
Kidney 0.27 0.18 0.64 0.93
Bladder 0.27 0.18 0.64 0.93
Brain, nervous system 0.68 0.18 0.75 0.93
Thyroid 0.27 0.18 0.64 0.93
Hodgkin lymphoma 0.55 0.19 0.75 0.93
Non-Hodgkin lymphoma 0.55 0.19 0.75 0.93
Multiple myeloma 0.19 0.19 0.75 0.93
Leukaemia 0.55 0.19 0.75 0.93
Data source: Dutch and Victorian burden of disease study and the Global
Burden of Disease project [3,5,6].
Estimates applied to all countries.
Soerjomataram et al. BMC Medical Research Methodology 2012, 12:125 Page 7 of 15
http://www.biomedcentral.com/1471-2288/12/125
Figure 2 Years lost due to disability (YLDs, white bar), years of life lost (YLLs, black bar) and disability-adjusted life years (DALYs, sum
of YLLs and YLDs) per 100,0000 in 2008 for Norway (a and b), Bulgaria (c and d), India (e and f) and Uganda (g and h). Estimates were
age standardised according to the world standard population and not discounted nor weighted (0,0).
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Sensitivity analyses
Observed versus modeled estimates of the proportion
cured/proportion treated and impact on DALYs
We validated the model-based estimates of proportion
cured and treated by comparing these with the observed
data from Norway (Table 4). Additionally, the model-
based country-specific estimates of the proportion trea-
ted were also validated by comparing these with observed
data from eight registries. The proportion cured and
treated estimated using our proposed method gave a rea-
sonably good fit with the observed values in Norway. As
for the other nations, the model-based estimates for pro-
portion treated were in line with those observed for good
prognosis cancers including colorectum (Figure 3), lar-
ynx, breast, cervix, prostate, testis, kidney, bladder,
thyroid and melanoma of the skin. While the model fit
was also acceptable for some poorer prognosis cancers
including lung, ovary, gallbladder and brain and nervous
system. Because an inverse in the relation between
human development index and proportion treated was
observed for pancreatic and liver cancer, we decided to
take the treatment proportion observed in Norway for all
countries. This is probably caused by the very poor sur-
vival of patients with these cancers causing an M:I
ratio ~ 1.
Finally Table 4 shows age-adjusted DALY rates for
Norway using the model-based estimates of the propor-
tion cured and the proportion treated, compared with
those calculated using observed values for these vari-
ables. The impact of using estimated values on the
Table 4 Observed (O) and estimated (E) values of proportion cured and treated, and age standardized disability-
adjusted life years (DALYs) per 100,000 population, by cancer in Norway in 2008 derived from observed estimates of
the proportion cured and proportion treated, versus expected values derived from models
Cancer sites Proportion cured (%) Proportion treated (%) DALYs a
O E O E O E
Lip oral cavity 39 33 91 77 46 45
Nasopharynx 39 35 91 81 3 3
Other pharynx 39 39 91 91 32 32
Oesophagus 11 10 52 46 80 79
Stomach 21 34 46 72 149 153
Colorectum 56 50 90 81 658 644
Liver 10 10 30b 30b 48 48
Gallbladder 16 38 34 79 34 34
Pancreas 6 5 27b 27b 248 248
Larynx 66 48 87 63 21 20
Lung 12 10 17 14 864 860
Melanoma of skin 80 76 95 90 181 180
Kaposi Sarcoma c 0 0 0 0 0 0
Breast 76 63 98 81 609 569
Cervix uteri 74 59 87 70 109 101
Corpus uteri 80 71 95 85 88 84
Ovary 35 30 83 72 155 153
Prostate 69 64 79 73 362 351
Testis 96 96 99 99 43 43
Kidney 47 46 80 79 108 108
Bladder 67 62 94 87 105 104
Brain, nervous system 64 26 83 34 282 272
Thyroid 89 89 95 95 11 11
Hodgkin lymphoma 86 90 91 95 11 11
Non-Hodgkin lymphoma 40 37 74 69 134 132
Multiple myeloma 37 34 68 62 66 66
Leukaemia 51 35 47 32 153 152
aNot discounted with equal age weight.
bObserved values were used to estimate DALY because inadequate fit of estimated values.
cIncidence and mortality in Norway from Kaposi Sarcoma was 0.
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overall DALYs was negligible, particularly for cancers of
the oesophagus, colorectum, endometrium, cervix, pros-
tate, testis, kidney, bladder, thyroid and Hodgkin lymph-
oma. More sizable differences were observed for cancers
of the breast, cervix uteri, corpus uteri and larynx (ran-
ging from 5-9% difference to the main results where
estimates were modeled).
Two- versus three-stage natural history models
The age adjusted DALYs per 100,000 for Norway, esti-
mated by the two-stage history model, are presented in
Table 5 (sensitivity analysis 1), and compared with the
observations using the 3-stage model (see Table 4).
Using this model and assuming all cancers patients were
treated, hardly affected the total DALY rates for most
cancer sites. Estimates for the DALYs were generally lar-
ger than those derived from the three-stage disease
model for good prognosis cancers such as breast and
prostate cancer. The percentage difference in DALY
rates, as compared to the three-stage disease model ran-
ged from 0% to 9%.
Advanced cancers as a proxy for untreated proportions
Table 5, sensitivity analysis 2, shows the effect on the
estimate of DALYs in Norway of using the observed
proportion of advanced cancers as a proxy for the pro-
portion treated. The largest difference in DALYs was only
observed for breast and prostate cancers, increasing the
estimates by 4% respectively, suggesting an overesti-
mation of DALYs, probably the result of overestimating
the proportion of patients who received curative treat-
ment. For thyroid, testicular and ovarian cancers, the
proportion of advanced cases was larger than the propor-
tion uncured so we did not perform this analysis for
these cancers. The stage distribution was not reported or
was not available for laryngeal, brain and nervous system
as well as haematological cancer, and was therefore omit-
ted from the analysis.
Impact of discounting and age weighting
As expected, compared with the basic model the rates of
DALYs after discounting and age weighing are much
lower. Discounting and age weighing did not substan-
tially change ranking of cancer sites. Generally we
observed an increase in the proportion of DALYs due to
YLDs after discounting and age weighting. The size and
direction of the effect varied by country, but the increase
in the YLDs:DALYs ratio was greatest in Uganda, and
generally larger for cancers of the brain, nervous system
and Hodgkin Lymphoma.
Discussion
In this paper we propose a methodology for estimation
of global disability-adjusted life years for cancer. Many
epidemiological variables are required to compute
DALYs in a single country according to the three-stage
natural history model, and, given the paucity of such
data (irrespective of quality) in many countries, the com-
pilation of DALYs at the global level is particularly chal-
lenging. Variables such as the proportion cured from, or
treated for different cancers, required in the calculation
of the YLDs, are unavailable in most countries, particu-
larly in low and middle income regions. The approach
outlined in this paper has produced a practical set of
estimates enabling cross-country comparisons of DALYs
and their two components, YLL and YLD. Such indica-
tors – over and above incidence, mortality and survival -
provide valuable additional information for planning and
Figure 3 Observed proportion treated in 8 cancer registries and estimated proportion worldwide for colorectal cancer.
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investing in cancer services within current health sys-
tems and help establish the need for population inter-
ventions aimed at reducing the burden of the disease.
Cancer survival has been increasing over the last four
decades in many more developed countries such as Nor-
way and Bulgaria. Inequalities in survival are reflected in
the larger proportion of the DALYs that are attributable
to YLD in these countries, compared to the less devel-
oped countries such as India or Uganda. Advances in
the treatment of several cancers - such oral cavity,
leukemia, testicular cancer has resulted in increasing
survival [34]. Earlier detection of breast, cervical and
colorectal cancer has increased the rate of treatable
cases and thus survival in developed countries [33]. Yet
facilities for cancer prevention, diagnosis and treatment
in developing countries remain inadequate, calling for
action to scale up these activities. In addition we also
observed large rates of DALYs attributed to highly pre-
ventable cancers such as lung, oral cavity or stomach in
all countries. This points to the importance of interven-
tion to reduce cigarette smoking. In Uganda, cancers
related to infection (Kaposi sarcoma, cervix cancer, non
Hodgkin lymphoma, liver cancer) make a large contribu-
tion in DALYs highlighting the value of vaccination or
treatment of the various infectious diseases.
Previous studies of the global burden of cancer were
performed by WHO as part of a wider effort to map the
global burden of disease in general [1,3]. This project,
commissioned in 1990 [3], introduced DALYs as a
means of facilitating comparison across diseases, coun-
tries and over time. In 2004, WHO published disease-
and country-specific DALYs [1], and their estimates are
generally comparable to our current estimates (as illu-
strated in Figure 4). Some differences can be attributed
to changing rates of incidence or mortality for some
cancer sites, as observed for lung cancer in Norway (de-
creasing) and in Bulgaria (increasing) [35]. The DALY
rates for breast, cervical and prostate cancer were rela-
tively high in the present study, most likely due to the
improvement in the YLD calculation, by incorporating a
more detailed disease quantification of phases and
sequelae.
This project has been followed by more recent assess-
ments of the global disease burden, as well as various
national initiatives [36-40]. These studies are mostly
confined to more developed countries, where similar
observations to our findings have been noted, with lung,
colorectal, and breast cancers sharing the largest propor-
tion of DALYs. Our study was able to draw on more
current epidemiological data to derive incidence and
mortality estimates [2,41], population-based data on can-
cer specific-treatment and outcomes including survival,
on the basis of more recent reviews [15-17,19]. A major
improvement in this study relative to previous studies is
the use of observed survival data in estimating the pro-
portion cured and the median survival of uncured
patients [13] as a means to calibrate country-specific
estimates of the proportion cured and proportion trea-
ted. In addition, larger lists of incorporated sequelae and
more information on the relative proportions of treated
and non-treated patients, using population based registry
data, will have resulted in a more valid set of estimates
than has been possible in previous exercises.
We modeled proportion cured based on the relation
between the mortality to incidence ratio and the human
development index. In an earlier paper we have shown a
strong correlation between gross domestic product
Table 5 Sensitivity analyses, age standardised disability-
adjusted life years (DALYs) per 100,000 population, and
percentage difference (%Diff) as compared to the main
analysis, Norway 2008
Cancer sites Sensitivity analysis 1a Sensitivity analysis 2b
DALYs %Diff DALYs %Diff
Lip oral cavity 46 2 46 2
Nasopharynx 3 0 3 0
Other pharynx 33 3 33 3
Oesophagus 80 1 80 1
Stomach 152 0 152 −1
Colorectum 643 1 643 0
Liver 48 0 48 0
Gallbladder 34 0 34 0
Pancreas 248 0 248 0
Larynx 20 5 - c - c
Lung 864 1 864 0
Melanoma of skin 180 1 180 0
Kaposi Sarcoma -d -d -d -d
Breast 587 4 587 3
Cervix uteri 102 1 102 1
Corpus uteri 84 1 84 0
Ovary 151 1 - e - e
Prostate 364 9 364 4
Testis 44 0 - e - e
Kidney 110 2 108 0
Bladder 105 1 105 1
Brain, nervous system 281 3 - c - c
Thyroid 11 0 - e - e
Hematological cancers - f - f - f - f
a Sensitivity analysis 1: Two-stage disease model as compared to three stage
disease model.
b Sensitivity analysis 2: Proportion of advanced cases used as proxy of patients
who did not receive (curatively intentioned) treatment as compared to use of
available treatment data.
c Staging data were not available.
d Treatment and staging data were not available.
e Proportion cured was larger than proportion of advanced cases, analysis was
not done.
f Sensitivity analyses 1 and 2 were not done for haematological cancers.
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(GDP) and cancer specific survival [2]. In this paper, HDI
was chosen over GDP because HDI that also covers
wealth, health and education [12] gave better fit than
GDP to survival in our internal analysis. This was con-
firmed on establishing reasonably well fitting models and
predicted estimates for the proportion cured on the basis
of HDI. The modeled proportion treated also corre-
sponded well to that reported by several cancer registries.
Finally the estimated DALYs in Norway based on the
modeling approach were very similar to those calculated
using observed data from the Registry, serving as further
indication of the validity of proportion cured and propor-
tion treated based on the former procedures.
The simpler two-stage [36] natural history model was
compared with the three-stage model to calculate
DALYs, in view of the principle that it may reduce the
complexity of the data required, and calculations. When
the two-stage model was used, it generally increased the
DALYs, although the differences with the three-stage
disease model were rather modest. In the two-stage dis-
ease model all patients received curative-intended treat-
ment, and thus all patients who would eventually die
from cancers went through remission followed by pre-
terminal and terminal phases. In this model, the increase
in time to death increased YLD. Therefore for cancers
with long remission times (for example, prostate cancer),
the differences between the two- and three-stage models
becomes larger.
As the intention of treatment (curative or palliative)
tends to be recorded less well than treatment modality,
we assumed that the proportion of patients receiving
any cancer treatment was a reasonable proxy of propor-
tion curatively treated. This is probably a slight overesti-
mation of the true proportion of patients who received
curative treatment, as was indicated by the sensitivity
analysis. We also considered the use of advanced cases
as a proxy of patients who did not receive curative treat-
ment; this had an effect of overestimating the YLD by up
to 4%. Such an observation likely resulted from a larger
proportion of YLD contributed by patients who were
treated but eventually died from cancer.
The limitations of this study pertain to the inputs and
necessary assumptions we have made, given the lack of
information available at the appropriate level of detail as
input for the calculation of DALYs. Firstly incidence and
mortality data were derived from the GLOBOCAN2008
Figure 4 Comparison of disability-adjusted live years per 100,000 (3% discounting and age weighting) for 13 cancers in Norway,
Bulgaria, India and Uganda, as estimated in the present study (current), and in the GBD study of WHO (WHO) [1].
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which are estimates with varying accuracy depending on
the availability of country-specific data [2]. In most low-
income countries, there are no comprehensive national-
level data on cancer incidence and mortality, and the
estimates are based on model-based rates of mortality
(from WHO) and/or limited data on cancer incidence
from regional cancer registries.
Secondly, the YLD calculations are based on rather
limited country-level data, and most parameters are
based on data from high-income countries. As an ex-
ample country-specific proportion cured was modeled
using survival:proportion cured ratio as observed in Nor-
way. Applying this ratio to other higher income country
may not cause substantial bias as treatment and follow-
up practices may be comparable. Third line treatments
might delay deaths from relatively advanced disease and
hence after “statistical” cure, patients may still have a
higher mortality relative to that observed in the general
population. On the other hand, it may be hypothesised in
less developed countries, treated patients who are con-
sidered cured effectively have a similar mortality experi-
ence to the general population. In such circumstances,
we may underestimate the proportion cured in the lower
and middle income countries.
Furthermore, we assumed a uniform period of two
months between onset of symptoms and treatment
(allowing for delays due to the patient and the medical
care system). While the duration of delay might be rea-
sonable for high income countries, it is probably too
optimistic in low and middle income settings. While
there are many population-specific studies related to
specific cancers [42-44], we are not aware of any overall
comparative assessment. In any case, a longer period of
disability in this phase is likely to be offset by shorter
pre-terminal and terminal phases: and the contributions
of YLDs from these disease phases comprise a very
small proportion of the cancer-specific DALYs in lower
income countries.
Fourthly, in calculating DALYs, we clearly missed
many long-term consequences from cancers. For ex-
ample infertility after chemotherapy for haematological
cancer patients is well reported [45], but we assumed
that these patients were completely cured from cancer.
In addition to the observable clinical sequelae many sur-
vivors continue to live with psychological stress related
to their cancer diagnosis [46]. The proportion living with
sequelae is calculated based on studies and data from
developed countries that may approximate the propor-
tion in countries with similar level of development. Yet,
in addition to low availability and access to modern can-
cer care, in developing countries cancer cases show a
less favorable stage distribution that requires more ag-
gressive treatment, hence a higher proportion of survi-
vors with cancer sequelae. Suboptimal treatment and
follow-up for cancer patients in less developed countries
may also cause higher levels of disability, and yet we
assumed similar disability weights for each sequelae in
all countries. Taking into account of these factors are
important in future studies where the burden and hence
the priorities in cancer control can be better determined.
Finally, the burden of disease study in Australia has
adjusted disability weight for common co-occurring dis-
eases, which we have not undertaken in this study [5].
Because we have assessed morbidity and disability due
to cancer only, the disability due to co-existing disease is
not considered in the analysis. In previous study where
burden from multiple diseases were estimated [5], a
down-weighting of the comorbidity avoided multiple-
counting of morbidities. For cancer the vast majority of
comorbidities will be less severe (e.g. arthritis, vision
problems etc.) and the comorbidity adjustments will not
be very large. For severe comorbidities where the adjust-
ment may be large, these will be very rare.
Conclusions
In this paper we have presented a methodological ap-
proach to derive the variables needed to compute DALYs
from cancer on a global scale. Such estimates should
help setting global priorities in health care with a view
to reducing the burden of cancer. The methodological
approach suggested in this study should enable all coun-
tries worldwide to calculate DALYs from cancer with a
reasonable degree of validity. Greater precision in the
sets of parameters used in this study would be provided
for by an enhancement of data availability and accuracy,
and the reporting of the relevant statistics required.
Based on the results of this study, it highlights the im-
portant role of prevention in reducing the cancer burden
given the large share of premature mortality from can-
cer, as estimated in the DALYs; even in a country with
high-quality cancer services such as Norway. Taking a
long-term perspective, a continuous global effort to in-
crease the awareness of prevention and treatment is
needed. This includes the provision of estimate of
DALYs as a means to assess the need for improvements
in early detection and treatment, thus reducing the exist-
ing inequalities in the availability and access to cancer
diagnostics and care.
Competing interests
The authors declare that we have no competing interests.
Authors' contributions
IS contributed to the data collection, study design, analysis and wrote the
first draft of the paper. JT contributed to the study design, analysis and
finalising the manuscript. JF contributed to the data collection and finalising
the manuscript. DF contributed to finalising the manuscript. DMP and CM
contributed to the study design and finalising the manuscript. FB
contributed to the study design and analysis and in drafting the manuscript.
All authors read and approved the final manuscript.
Soerjomataram et al. BMC Medical Research Methodology 2012, 12:125 Page 13 of 15
http://www.biomedcentral.com/1471-2288/12/125
Acknowledgements
During the project IS was partially supported by the International Agency for
Research on Cancer Fellowship Programme, by Rubicon from the Dutch
Scientific Society and the EUR Fellowship. We acknowledge the contribution
of cancer registries in the provision of treatment data and thank Eric
Chokunonga, Nadia Dimitrova, Fiona Dwane, Ryszard Mężyk, Omar Nimri. No
funding body had a role in the study design; in the collection, analysis, and
interpretation of data; in the writing of the manuscript; and in the decision
to submit the manuscript for publication.
Author details
1Department of Public Health, Erasmus MC, Rotterdam, the Netherlands.
2Department of Global Health and Population, Harvard School of Public
Health, Boston, USA. 3Section of Cancer Information, International Agency for
Research on Cancer, 150 Cours Albert Thomas, Lyon 69372, France. 4World
Health Organization, Geneva, Switzerland. 5Clinical Trial Service Unit and
Epidemiological Studies Unit, University of Oxford, Oxford, UK.
Received: 14 September 2011 Accepted: 18 May 2012
Published: 17 August 2012
References
1. World Health Organization: The global burden of disease: 2004 update.
Geneva: World Health Organization; 2008.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010,
127:2893–2917.
3. Murray CLM, Lopez AD: The Global Burden of Disease. Boston: Harvard
School of Public Health; 1996.
4. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW,
Santaquilani M, group EW: Survival for eight major cancers and all
cancers combined for European adults diagnosed in 1995–99: results of
the EUROCARE-4 study. Lancet Oncol 2007, 8(9):773–783.
5. Victorian burden of disease study: Mortality and morbidity in 2001.
Melbourne: The Public Health Group, Rural and Regional Health and Aged
Care Services Division. Victorian Government Department of Human
Services; 2005.
6. Stouthard M, Essink-Bot ML, Bonsel G, Barendregt J, Kramers PG: Disability
weights for diseases in the Netherlands. Rotterdam: Department of Public
Health, Erasmus University; 1997.
7. Murray CJ: Quantifying the burden of disease: the technical basis for
disability-adjusted life years. Bull World Health Organ 1994, 72(3):429–445.
8. Doll R, Payne P, Waterhouse JAH: Cancer incidence in five continents, vol. 1.
Geneva: Union Internationale Contre le Cancer; 1966.
9. Lambert PC, Thompson JR, Weston CL, Dickman PW: Estimating and
modeling the cure fraction in population-based cancer survival analysis.
Biostatistics 2007, 8(3):576–594.
10. Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality
from 25 cancers in 1990. Int J Cancer 1999, 83(1):18–29.
11. Asadzadeh Vostakolaei F, Karim-Kos HE, Janssen-Heijnen ML, Visser O,
Verbeek AL, Kiemeney LA: The validity of the mortality to incidence ratio
as a proxy for site-specific cancer survival. Eur J Public Health 2011,
21(5):573–577.
12. United Nations Development Programme: Human Development Reports
2011: Sustainability and equitability. A better future for all. New York: United
Nations Development Programme; 2011.
13. Småstuen M, Aagnes B, Johannesen TB, Møller B, Bray F: Long-term cancer
survival: patterns and trends in Norway 1965–2007. Oslo: Cancer Registry of
Norway; 2008.
14. de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen
ML, Coebergh JW: Superior survival of females among 10,538 Dutch
melanoma patients is independent of Breslow thickness, histologic type
and tumor site. Ann Oncol 2008, 19(3):583–589.
15. Kvale R, Moller B, Angelsen A, Dahl O, Fossa SD, Halvorsen OJ, Hoem L,
Solberg A, Wahlqvist R, Bray F: Regional trends in prostate cancer
incidence, treatment with curative intent and mortality in Norway
1980–2007. Cancer Epidemiol 2010, 34(4):359–367.
16. Johansson E, Bill-Axelson A, Holmberg L, Onelov E, Johansson JE, Steineck
G, Scandinavian Prostate Cancer Group Study N: Time, symptom burden,
androgen deprivation, and self-assessed quality of life after radical
prostatectomy or watchful waiting: the Randomized Scandinavian
Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol
2009, 55(2):422–430.
17. Brydoy M, Fossa SD, Klepp O, Bremnes RM, Wist EA, Wentzel-Larsen T, Dahl
O: Paternity following treatment for testicular cancer. J Natl Cancer Inst
2005, 97(21):1580–1588.
18. Fossa SD, Ous S, Espetveit S, Langmark F: Patterns of primary care and
survival in 336 consecutive unselected Norwegian patients with bladder
cancer. Scand J Urol Nephrol 1992, 26(2):131–138.
19. Hardt J, Filipas D, Hohenfellner R, Egle UT: Quality of life in patients with
bladder carcinoma after cystectomy: first results of a prospective study.
Qual Life Res 2000, 9(1):1–12.
20. Organisation for Economic Co-operation and Development: OECD Health
Data 2010. Paris: Organisation for Economic Co-operation and
Development; 2010.
21. Comprehensive Cancer Centre the Netherlands: Cancer clinical practice
guideline. Utrecht: Comprehensive Cancer Centre the Netherlands; 2002.
http://www.oncoline.nl/index.php?language=en.
22. Morris E, Quirke P, Thomas JD, Fairley L, Cottier B, Forman D: Unacceptable
variation in abdominoperineal excision rates for rectal cancer: time to
intervene? Gut 2008, 57(12):1690–1697.
23. Allemani C, Storm H, Voogd AC, Holli K, Izarzugaza I, Torrella-Ramos A,
Bielska-Lasota M, Aareleid T, Ardanaz E, Colonna M, et al: Variation in
'standard care' for breast cancer across Europe: a EUROCARE-3 high
resolution study. Eur J Cancer 2010, 46(9):1528–1536.
24. Cancer Registry of Norway. Cancer in Norway 2008: Cancer incidence,
mortality, survival and prevalence in Norway. Oslo: Cancer Registry of
Norway; 2009.
25. Bray F, Engholm G, Hakulinen T, Gislum M, Tryggvadottir L, Storm HH, Klint
A: Trends in survival of patients diagnosed with cancers of the brain and
nervous system, thyroid, eye, bone, and soft tissues in the Nordic
countries 1964–2003 followed up until the end of 2006. Acta Oncol 2010,
49(5):673–693.
26. Bray F, Klint A, Gislum M, Hakulinen T, Engholm G, Tryggvadottir L, Storm
HH: Trends in survival of patients diagnosed with male genital cancers in
the Nordic countries 1964–2003 followed up until the end of 2006. Acta
Oncol 2010, 49(5):644–654.
27. Engholm G, Hakulinen T, Gislum M, Tryggvadottir L, Klint A, Bray F, Storm
HH: Trends in the survival of patients diagnosed with kidney or urinary
bladder cancer in the Nordic countries 1964–2003 followed up to the
end of 2006. Acta Oncol 2006, 49(5):655–664.
28. Hakulinen T, Engholm G, Gislum M, Storm HH, Klint A, Tryggvadottir L, Bray
F: Trends in the survival of patients diagnosed with cancers in the
respiratory system in the Nordic countries 1964–2003 followed up to the
end of 2006. Acta Oncol 2006, 49(5):608–623.
29. Hakulinen T, Tryggvadottir L, Gislum M, Storm HH, Bray F, Klint A, Engholm
G: Trends in the survival of patients diagnosed with cancers of
the lip, oral cavity, and pharynx in the Nordic countries
1964–2003 followed up to the end of 2006. Acta Oncol 2010,
49(5):561–577.
30. Rayson D, Saint-Jacques N, Younis T, Meadows J, Dewar R: Comparison of
elapsed times from breast cancer detection to first adjuvant therapy in
Nova Scotia in 1999/2000 and 2003/04. CMAJ 2007, 176(3):327–332.
31. van Steenbergen LN, Lemmens VE, Rutten HJ, Martijn H, Coebergh JW: Was
there shortening of the interval between diagnosis and treatment of
colorectal cancer in southern Netherlands between 2005 and 2008?
World J Surg 2010, 34(5):1071–1079.
32. Anand S, Hanson K: Disability-adjusted life years: a critical review. J Health
Econ 1997, 16(6):685–702.
33. Sankaranarayanan R, Boffetta P: Research on cancer prevention, detection
and management in low- and medium-income countries. Ann Oncol
2010, 21(10):1935–1943.
34. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, Atun R,
Blayney D, Chen L, Feachem R, et al: Expansion of cancer care and control
in countries of low and middle income: a call to action. Lancet 2010,
376(9747):1186–1193.
35. Bray FI, Weiderpass E: Lung cancer mortality trends in 36 European
countries: secular trends and birth cohort patterns by sex and region
1970–2007. Int J Cancer 2010, 126(6):1454–1466.
36. Alvarez-Martin E, Morant-Ginestar C, Genova-Maleras R, Gil A, Perez-Gomez
B, Lopez-Abente G, Fernandez de Larrea-Baz N: Burden of disease due to
cancer in Spain. BMC Publ Health 2009, 42:9–42.
Soerjomataram et al. BMC Medical Research Methodology 2012, 12:125 Page 14 of 15
http://www.biomedcentral.com/1471-2288/12/125
37. Michaud CM, McKenna MT, Begg S, Tomijima N, Majmudar M, Bulzacchelli
MT, Ebrahim S, Ezzati M, Salomon JA, Kreiser JG, et al: The burden of
disease and injury in the United States 1996. Popul Health Metr 2006, 4:11.
38. Jankovic S, Vlajinac H, Bjegovic V, Marinkovic J, Sipetic-Grujicic S,
Markovic-Denic L, Kocev N, Santric-Milicevic M, Terzic-Supic Z, Maksimovic
N, et al: The burden of disease and injury in Serbia. Eur J Public Health
2007, 17(1):80–85.
39. Murthy NS, Nandakumar BS, Pruthvish S, George PS, Mathew A: Disability
adjusted life years for cancer patients in India. Asian Pac J Cancer Prev
2010, 11(3):633–640.
40. Phua HP, Chua AV, Ma S, Heng D, Chew SK: Singapore's burden of disease
and injury 2004. Singapore Med J 2009, 50(5):468–478.
41. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61(2):69–90.
42. Pineros M, Sanchez R, Perry F, Garcia OA, Ocampo R, Cendales R: Delay for
diagnosis and treatment of breast cancer in Bogota, Colombia. Salud
Publica Mex 2011, 53(6):478–485.
43. Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW: Cancer
care challenges in developing countries. Cancer 2011.
44. Sulu E, Tasolar O, Berk Takir H, Yagci Tuncer L, Karakurt Z, Yilmaz A: Delays
in the diagnosis and treatment of non-small-cell lung cancer. Tumori
2011, 6:693–697.
45. Knopman JM, Papadopoulos EB, Grifo JA, Fino ME, Noyes N: Surviving
childhood and reproductive-age malignancy: effects on fertility and
future parenthood. Lancet Oncol 2010, 11(5):490–498.
46. Holterhues C, Cornish D, van de Poll-Franse LV, Krekels G, Koedijk F, Kuijpers
D, Coebergh JW, Nijsten T: Impact of melanoma on patients' lives among
562 survivors: a dutch population-based study. Arch Dermatol 2011,
147(2):177–185.
doi:10.1186/1471-2288-12-125
Cite this article as: Soerjomataram et al.: Estimating and validating
disability-adjusted life years at the global level: a methodological
framework for cancer. BMC Medical Research Methodology 2012 12:125.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Soerjomataram et al. BMC Medical Research Methodology 2012, 12:125 Page 15 of 15
http://www.biomedcentral.com/1471-2288/12/125
